Also known as cachectin, TNF, TNF-α, TNF-alpha, and TNFSF2.
Peptide-based TNFR1 antagonist discovered with PeptiDream showed activity in animal models; Japan trial began Apr 19 to evaluate PK, safety and tolerability of subcutaneous doses in healthy volunteers
Merck starts Phase 2b trials for tulisokibart in hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis, targeting over 640 patients globally.
